The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Ritlecitinib, a Janus Kinase 3 and Tyrosine-Protein Kinase Family Inhibitor, in Humans

Determination of mean valproic acid serum level by assay of a single pooled sample

Robert A. Hamilton, William R. Garnett, Berry J. Kline · Clinical Pharmacology & Therapeutics · 1981 · 256 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results

Brett King, Emma Guttman‐Yassky, Elena Peeva et al. · Journal of the American Academy of Dermatology · 2021 · 193 citations · Full text

Medicine, Dermatology, Pharmacology +15

Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2<i>S</i>,5<i>R</i>)-5-((7<i>H</i>-Pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans

Atli Thorarensen, Martin E. Dowty, Mary Ellen Banker et al. · Journal of Medicinal Chemistry · 2017 · 165 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor

Hua Xu, Michael I. Jesson, Uthpala Seneviratne et al. · ACS Chemical Biology · 2019 · 161 citations

Life Sciences, Medicinal Chemistry, Pharmacology +15

Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers

Emma Guttman‐Yassky, Ana B. Pavel, Aisleen Diaz et al. · Journal of Allergy and Clinical Immunology · 2021 · 96 citations · Full text

Medicine, Dermatology, Pharmacology +16